New triple-drug attack targets hard-to-treat liver cancer
NCT ID NCT07010497
First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times
Summary
This study tests a new drug, Irpagratinib, added to two standard drugs (Atezolizumab and Bevacizumab) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if the combination is safe and shrinks tumors. About 33 adults with a specific genetic marker (FGF19 overexpression) will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, HEPATOCELLULAR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Asan Medical Center,
RECRUITINGSeoul, South Korea
-
Seoul National University Hospital
NOT_YET_RECRUITINGSeoul, South Korea
-
Severance Hospital
NOT_YET_RECRUITINGSeoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple belly press make liver cancer radiation more precise?
- A new way to read CT scans may predict which liver surgery patients will develop Life-Threatening failure
- Virus hunts liver tumors before chemo strikes
- New combo therapy aims to stop liver cancer from coming back
- Modified virus injected into tumors shows promise for liver cancer
- New hope for kids with rare liver tumors: tailored therapy trial shows promise